Carriage of a BRCA1/2 mutation was associated with improved short-term survival but provided no long-term survival benefit in a cohort of women with ovarian cancer, according to study results.
The researchers conducted the prospective analysis to determine whether carriage of a BRCA1 or BRCA2 mutation affected survival outcomes.
The researchers identified eligible participants who had been diagnosed with invasive ovarian cancer in Ontario, Canada, or Tampa, Fla., between 1995 and 2004.
The analysis included 1,626 patients, of whom 218 carried BRCA1/2 mutations. None of the patients were aware of their genetic status at the time of diagnosis. Results were not shared with patients until at least 1 year elapsed from diagnosis, so patients’ genetic status did not influence treatment decisions, according to the researchers.
The mean follow-up was 6.9 years (range, 0.3-15.7 years).
Mutation was associated with better prognosis at 3 years after diagnosis (adjusted HR=0.68, 95% CI, 0.48-0.98). However, at the 10-year mark, the HR was 1.00 (95% CI, 0.83-1.22).
Among women with serous disease, 27.4% of those with a BRCA1 mutation, 27.7% of those who carried BRCA2 and 27.1% of noncarriers were still alive 12 years after diagnosis.
“We believe that there is insufficient evidence to conclude that survival from ovarian cancer differs between carriers and noncarriers,” the researchers wrote. “We disagree with the recommendation that health-care providers should counsel women with ovarian cancer and carrying BRCA mutations that they should expect their survival to be better than that of noncarriers or that treatment could be tailored to reflect the differences in survival.”